Post Reply
3061-3080 of 10899
We have to thank him. We got BIG cheap from him :)
infancybird ( Date: 09-May-2011 15:12) Posted:
|
Agree, but it also makes BIG an attractive target for those who lagging behind...read the likes of J& J..... my uneducated guess.
metaphoricsymbol ( Date: 11-May-2011 15:04) Posted:
|
Why need to watch out for Biosensor's competitors:
“April 26, 2011—Toronto—According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, change in the dynamic Japanese drug eluting stent (DES) market is set to continue over the next five years. Abbott Vascular rapidly gained a 40 percent share of the DES market with the release of its XIENCE V stent in 2010. Terumo Medical is expected to capture at least a 20 percent share fairly rapidly when it introduces its Nobori stent later in 2011. A number of other innovative stents are expected to enter the market between now and 2015, keeping competitive pressure high. . . .
Abbott product, XIENCE PRIME, in 2012. In response to this competition, Boston Scientific and Cordis are working to get their own next-generation stents onto the Japanese market, Boston Scientific with its PROMUS Element and Cordis with NEVO, before they see further erosion of their own market shares. And it won’t stop there expect a lot of competition in this market for the foreseeable future.”
Still wondering where is our forever shortist abyexpres who likes to eat roasted duck and pig using money he earned from shorting BIG. Have not heard from him lately.....still nursing his worm- infested stomach in intensive care unit due to eating left over meat as he got no money to buy fresh duck as he has no chance to short and hence quite broke by now. He referrred us as his roasted pig/duck in some of his earlier postings.
swissvic ( Date: 09-May-2011 14:49) Posted:
|
FOR INFORMATION.
BUY IN BY CDP FROM 21/4--5/5.
ONLY TWO BUYIN BY CDP.
21/4 ----50,000 at 1.34 ==$67,000
29/4 ---38,000 at $1.37 == $52,060
WHAT SHORTING IS THERE ? only 88 lots
I doubt EuroPCR is the catalyst for this current run up...
metaphoricsymbol ( Date: 09-May-2011 09:27) Posted:
|
Coming EuroPCR is interesting to watch - Beware. It is just next week.
Must not only listen to Biosensors, but look out for competitors announcements.
Not a call to buy or sell (though I have sold my last 20% (70 lots) of Biosensors at 1.370) recently.
Will stay at sideline to watch.
The technical picture for Biosensors continues to look strong, despite its overbought situation. (somewhat ameliorated by mild pullbacks).
Unless there is some bad news (which looks unlikely at the moment), the stock may test resistance of 1.41, and eventually the area between 1.46 to 1.52 (1.52 is the stock all time high achieved in oct 2005 !).
Potential catalyst going forward will be the EuropPCR clinical conference to be held between 17th May - 20th May. (details of what will be presented is in Biosensors' website), where the bifurcation DES, Devax will be officially launched.
Also, this will be followed by its full yr results, around 25-26th may, and the eagarly anticipated 12 mths projection, which the company normally gives. (So far, the company has fulfilled its projections, and to some extent exceeded it).
Not a call to buy/sell.
On another topic, Transcu, another life science company looks interesting, but it is in an even worse state than Biosensors was in early 2007-2008, but nevertheless, an interesting company to watch out for, although there is a possibility, that they will run out of cash, before realising their full potential (look at the Transcu heading for more info).
Also, not a call to buy/sell Transcu.
DBS Vickers Andy Sim reported that the JV agreement with Shangdong Weigao allowing JW Medical System to market Biosensors` stent expires in 2013 and it is under negotiation for renewal as it is too valuable for either to give up. JWMS is estimated to be worth US 1 Billion and contributed US $ 15 million to Biosensors` topline in FY 2010. JWMS has 18.5% of stent market in China which was value at RMB 5.71 Bil and will grow to RMB 17 billion in 2014. The new shareholder like Atlantis and Ever Union can help to unlock and enhance value of Biosensor in PRC thru their connection in China.
Biosensor make only drug stent which account for some 90% of turnover and this make M& A and opening new market particularly important . The $200 million it recently acquired thru share placement will come to good use to acquire new product and do new Clinical trials. Japan and China are the two markets that the coy is focusing now . OCBC Analsyt Wong has also a buy call for BIG with a target price of $ 1.48.
topdog22 ( Date: 07-May-2011 10:19) Posted:
|
that would be nice BUT anything official???
Dual-listing in HKSE or NASDAQ?
topdog22 ( Date: 06-May-2011 17:56) Posted:
|
must be getting ready for announcement. Any ideas?
today closed at 1.38 with 248,000 done closing.
1.36 956,000
1.37 2,864,000
1.38 1,362,000
total trade 6,422,000 done
expect share move further next week.
eh sorry bt the relation?
Shanghai Pharmaceuticals Holding Co., China’s second-largest drug distributor, will sell new shares to Temasek Holdings Pte and Pfizer Inc. in an offering in Hong Kong of as much as US$2.2 billion ($2.69 billion) of stock to fund acquisitions.
Temasek, a Singapore state investment company, Pfizer, Guoco Group and Bank of China Group Investment will buy a total of US$550 million shares for HK$21.80 to HK$26 apiece, according to a marketing document sent to investors today.
The funds will enable Shanghai Pharma to buy manufacturing assets in China, where demand for medicines is forecast by IMS Health Inc. to expand at least 25% this year. A soon-to- be-released government plan may push for the nation’s three biggest drug companies to increase their share of the market to 30% to 35% by 2015 from 21% in 2009, the 21st Century Business Herald reported last week.
“Shanghai Pharma should benefit from upcoming industry consolidation, since it is already one of the biggest players,” said Pan Lei, an analyst at Beijing-based Guodu Securities Co., who recommends buying the shares. “The company is seen as an attractive investment because its drug distribution business makes it stable.”
Shanghai Pharma, the first drugmaker in China licensed to make Roche Holding AG’s Tamiflu medicine, plans to sell a total of 664.2 million shares in the Hong Kong offering. Temasek will invest US$300 million, Guoco Group will invest US$150 million, and Pfizer and Bank of China Group Investment will each buy US$50 million of shares, according to the document.
allright ( Date: 30-Apr-2011 14:53) Posted:
|
I have got big windfall in this counter, and am now selling everything at between 1.30 to 1.35. Play safe, and use the $$ for other counters that have not gone up much. Looking, looking, looking.
allright ( Date: 30-Apr-2011 14:53) Posted:
|
On the 27-4-2011 market done 18.653m of BIG and range of 1.32 to 1.37.
Not a call to buy or sell .
infancybird ( Date: 29-Apr-2011 21:37) Posted:
|
|
Bing Yuan
Managing Director, Beijing Hony Future Investment Advisor Ltd.
|
9
9
|
| Age | Total Annual Compensation | This person is connected to 1 Board Members in 1 different organizations across 1 different industries. See Board Relationships |
| -- | -- |
CORPORATE HEADQUARTERS6th floor South Tower CBeijing, Beijing Province 100190 China Phone: 86 10 8265 5888 Fax: 86 10 8265 5800 Board Members MEMBERSHIPS2010-Present
Non-Executive Director, Member of Audit Committee and Member of Compensation Committee
EDUCATIONMaster's Degree 1993
Yale University
BA 1990
NanJing University
Doctorate 1998
Yale Law School
OTHER AFFILIATIONS |
ANNUAL COMPENSATIONThere is no Annual Compensation data available.STOCK OPTIONSThere is no Stock Options data available.TOTAL COMPENSATIONThere is no Total Compensation data available. |
The company just reported that its substantial share holder (FMR,FIL gp) has ,on 27-4-2011, purchased 4.3million shares in the open market . Share holding is raised from 5.74% to 6.06%. Big boy buying at around $1.35 - 1.36 which is yesterday`s price . Something cooking?? or BB knows things that we don`t know. Is this stock still overprice ? as suggested by forum member tmchai.
tmchai ( Date: 28-Apr-2011 09:32) Posted:
|
J& J (Johnson & Johnson) may have more on its overseas shopping list. The US health giant's US$21.3 billion purchase of Swiss-listed, US-incorporated Synthes is its largest ever.
A big deal seemed like a way for J& J to deploy its US$28 billion of cash, largely trapped overseas. But as it turns out it is paying mostly in stock.
Using equity for an overseas deal is often a non- starter. The target's shareholders, usually mainly domestic, may not want foreign shares - and might quickly dump them if they got them. Merger arbitrageurs, whose votes can be critical to getting a deal approved by shareholders, generally prefer cash.
And for a US acquirer, bringing overseas cash home triggers a tax liability, so it's better used for offshore acquisitions.
Yet J& J is paying 65 per cent of the deal price in stock.
One possible reason is that Synthes founder Hansjoerg Wyss and his family foundations own 48 per cent of the company. He has pledged at least 33 per cent of votes in favour of the transaction, suggesting it is likely to be approved.
Mr Wyss may be perfectly happy with J& J shares. Moreover, since he is above the traditional retirement age, taking stock may be preferable for estate tax planning purposes.
As for J& J, the equity component will put less strain on its AAA credit rating. Moody's affirmed the rating after the deal was announced, but revised its outlook to negative from stable.
Assuming J& J hangs onto its top-rated status, it will be one of only a handful of companies that have done so.
Keeping it that way may partly be vanity - there's little funding cost advantage over a slightly lower-rated corporate borrower. But the company seems to think it's important.
Either way, the result is that after the deal J& J will still have a large and growing treasure chest overseas, and the incentive to use it abroad rather than bring it home. Moreover, sales of everything from over-the-counter medicine to surgical equipment are growing faster in developing countries than in the United States.
J& J has had problems with a series of product recalls. On top of that, it has just agreed the largest acquisition in its history. But the transaction structure suggests the company may have further deals in mind.
A big deal seemed like a way for J& J to deploy its US$28 billion of cash, largely trapped overseas. But as it turns out it is paying mostly in stock.
Using equity for an overseas deal is often a non- starter. The target's shareholders, usually mainly domestic, may not want foreign shares - and might quickly dump them if they got them. Merger arbitrageurs, whose votes can be critical to getting a deal approved by shareholders, generally prefer cash.
And for a US acquirer, bringing overseas cash home triggers a tax liability, so it's better used for offshore acquisitions.
Yet J& J is paying 65 per cent of the deal price in stock.
One possible reason is that Synthes founder Hansjoerg Wyss and his family foundations own 48 per cent of the company. He has pledged at least 33 per cent of votes in favour of the transaction, suggesting it is likely to be approved.
Mr Wyss may be perfectly happy with J& J shares. Moreover, since he is above the traditional retirement age, taking stock may be preferable for estate tax planning purposes.
As for J& J, the equity component will put less strain on its AAA credit rating. Moody's affirmed the rating after the deal was announced, but revised its outlook to negative from stable.
Assuming J& J hangs onto its top-rated status, it will be one of only a handful of companies that have done so.
Keeping it that way may partly be vanity - there's little funding cost advantage over a slightly lower-rated corporate borrower. But the company seems to think it's important.
Either way, the result is that after the deal J& J will still have a large and growing treasure chest overseas, and the incentive to use it abroad rather than bring it home. Moreover, sales of everything from over-the-counter medicine to surgical equipment are growing faster in developing countries than in the United States.
J& J has had problems with a series of product recalls. On top of that, it has just agreed the largest acquisition in its history. But the transaction structure suggests the company may have further deals in mind.